Abstract |
The use of isolated regional perfusion in an adjuvant setting for stage I melanoma of the extremity continues to be controversial. The present retrospective study evaluates the past 20 years' experience by comparing 227 perfused patients from Groningen with 238 matched controls from five hospitals in The Netherlands and Westphalia (a region of West Germany bordering the Netherlands). All patients underwent wide local excision for a primary extremity melanoma of 1.5 mm or greater in thickness. A proportional hazards regression analysis for recurrence of disease and survival identified the significant prognostic factors, of which tumor thickness was the most important. Corrected for these factors, it was not possible to demonstrate a statistically significant effect for perfusion in terms of time to limb recurrence (P = .61), time to regional lymph node metastasis ( P = .11), time to distant metastasis (P = .73), disease-free interval (P = .42), and survival (P = .90). No statistically significant differences were seen for adjuvant perfusion in any of the subgroups.
|
Authors | H R Franklin, H Schraffordt Koops, J Oldhoff, B M Czarnetzki, E Macher, B B Kroon, K Welvaart, J W van der Velden, E van Dijk, E P van der Esch |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 6
Issue 4
Pg. 701-8
(Apr 1988)
ISSN: 0732-183X [Print] United States |
PMID | 3357008
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adult
- Combined Modality Therapy
- Female
- Follow-Up Studies
- Humans
- Male
- Melanoma
(drug therapy, pathology, surgery)
- Melphalan
(administration & dosage, therapeutic use)
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Recurrence, Local
- Neoplasm Staging
- Perfusion
- Retrospective Studies
- Skin Neoplasms
(drug therapy, pathology, surgery)
|